Information Provided By:
Fly News Breaks for March 30, 2017
MGNX
Mar 30, 2017 | 16:32 EDT
Raymond James analyst Reni Benjamin initiated MacroGenics with an Outperform and a $26 price target saying it is a unique "marquee" player in the bispecific antibody space. The analyst believes the value of MacroGenics' DART platform, the newsflow from multiple trials, the potential to sign additional global marquee partners, and a cash position of $245M represent an unique opportunity.
News For MGNX From the Last 2 Days
There are no results for your query MGNX